Biomarkers for Prostate Cancer
In the last decade, revolutionary advancements in molecular profiling technologies have been made resulting in new diagnostic algorithms. These advances have marked the beginning of a new era for modern medicine: individualized medicine. Biomarkers are important tools in individualized medicine, to accurately predict the biological behavior and therapy response for well-stratified/homogeneous groups of patients. This chapter will focus on established biomarkers for prostate cancer and promising novel biomarkers, arranged by tissue markers, blood markers, and urine markers. Many new biomarkers are ready for “prime time,” yet it needs carefully designed studies to test the exact clinical positioning. The STARD (standards for reporting of diagnostic accuracy) statement and the REMARK guidelines (reporting recommendations for tumor marker prognostic studies) are two initiatives that are important steps forward in improving the quality of tumor marker studies.
KeywordsProstate Cancer Radical Prostatectomy Digital Rectal Examination Aggressive Prostate Cancer Prostate Cancer Prevention Trial
- Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95Google Scholar
- Herrala AM, Porvari KS, Kyllonen AP et al (2001) Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 92:2975–2984PubMedGoogle Scholar
- Minner S, Enodien M, Sirma H et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of anti-hormonal therapy. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-11-1251